Risofos 150 mg Tablet (Risedronate 150mg)

Risofos 150 mg Tablet

Risofos 150Mg Tablet is a medicine for treatment and cure of osteoporosis. Osteoporosis is a type of bone disease which results in bone loss and makes them thinner and easily breakable. The medicine strengthens the bones and treat Pagets disease as well. It is usually administered orally, and doses have long gaps between them. Osteoporosis is more common in older people, and women who have gone through menopause. Risofos 150Mg Tablet slows down bone loss, and it belongs to the class of drugs called bisphosphonates.

Any esophageal problem, difficulty in swallowing of food, low blood calcium levels which is known as hypocalcemia or any other severe kidney, stomach and intestine disorders must be communicated to the doctor before the medication of Risofos 150Mg Tablet starts. The dentist should be informed about this medicine before any dental procedure is done on the patient.

Upset stomach is one of the most common side effects of this disease which may even lead to diarrhea. Rare side effects like increase in joint pain, muscle pain, vision blurring etc may also be noticed. This medication should only be taken under doctor’s supervision. The doctor may as well advice additional medicines for supplying calcium and Vitamin D to the bones along with this medicine.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Orthopedic Doctor before using this medicine.

Use

Osteoporosis

Related Product

Risofos 35 mg Tablet
Risofos 150 mg Tablet

Side Effects

Headache

Abdominal Distension

Acid Reflux

Abdominal Pain

Difficulty In Swallowing

Flatulence

Dyspepsia

Musculoskeletal Bone

Muscle Or Joint Pain

Constipation

Diarrhoea

Esophageal Ulcer

Dosage

Are there any missed dose instructions?

If you miss a dose of Risedronate, skip it and continue with your normal schedule. Do not double the dose.

Work

This medicine is used in the treatment of osteoporosis. The drug affects hydroxyapatite and inhibits FPP synthase, thereby halting the biosynthesis of isoprenoid lipids. As a result bone reabsorption and turnover is reduced.